CBD Novel Food: a new step forward
On January 4, 2021, addressing the food supplements market, Spectrums Europe presented applications for authorization under the Novel Foods Regulation of two of its flagship products – its CBD isolate 99% and its Broad Spectrum Hemp extract –. Today, we are happy to announce that we have reached a new important step in the process.
In Europe, the most advanced French applications
17 CBD dossiers of natural origin are currently under study by EFSA. The Spectrums applications are the only ones filed by a French company and concern natural extracts of Cannabis sativa L.
In October 2021, the two application passed a new stage (Suitability complete) in the constitution and validation process preceding the safety assessment phase by the European Union and EFSA.
In the UK, more than 500 products related to our applications
At the same time, and following the Brexit, Spectrums Europe has initiated a similar process with the FSA in the United Kingdom. The FSA has authorized all the brands that have been selling CBD products before February 13, 2020 to remain on the UK market, provided a novel food application has been filed before the end of March 2021. 61 brands and 553 products are currently related to Spectrums Europe’s applications. 3 of these brands are drinks brands, 1 of which is Botanic Lab.
